ArticleACS synthetic biology2019
Inducible Gene Switches with Memory in Human T Cells for Cellular Immunotherapy.
Article in ACS synthetic biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Programmable promoter editing for precise control of transgene expression.Nature biotechnology · 2026Article
- Engineering programmable CAR and antigen pairing via drug-gated light activation.Nature communications · 2026Article
- Role of tumor microenvironment in regulator of tumor progression and immunotherapy.Discover oncology · 2026Review
- Small-molecule control of CAR T cells.Nature reviews. Chemistry · 2025Review
- Multiplexing light-inducible recombinases to control cell fate, Boolean logic, and cell patterning in mammalian cells.Science advances · 2025Article
- Chemical genetic control of cytokine signaling in CAR-T cells using lenalidomide-controlled membrane-bound degradable IL-7.Leukemia · 2024Article
- The Challenges to Advancing Induced Pluripotent Stem Cell-Dependent Cell Replacement Therapy.Medical research archives · 2023Article
- Small molecule-inducible gene regulatory systems in mammalian cells: progress and design principles.Current opinion in biotechnology · 2022Review
- Recent progress of gene circuit designs in immune cell therapies.Cell systems · 2022Review
- Design and characterization of a salicylic acid-inducible gene expression system for Jurkat cells.Journal of biotechnology · 2022Article
- Theranostic cells: emerging clinical applications of synthetic biology.Nature reviews. Genetics · 2021Review
- Quantitative characterization of recombinase-based digitizer circuits enables predictable amplification of biological signals.Communications biology · 2021Article
- Compact Bidirectional Promoters for Dual-Gene Expression in a Sleeping Beauty Transposon.International journal of molecular sciences · 2020Article
- A mechanistic model of the BLADE platform predicts performance characteristics of 256 different synthetic DNA recombination circuits.PLoS computational biology · 2020Article
- Small-molecule inducible transcriptional control in mammalian cells.Critical reviews in biotechnology · 2020Review
- Tuning up Transcription Factors for Therapy.Molecules (Basel, Switzerland) · 2020Review
- Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis.Biomedicines · 2020Review
- Mechanistic modelling of tyrosine recombination reveals key parameters determining the performance of a CAR T cell switching circuit.Engineering biology · 2020Article
- Synthetic Biology Speeds Up Drug Target Discovery.Frontiers in pharmacology · 2020Review
- Synthetic immunity by remote control.Theranostics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cell-based therapies that employ engineered T cells-including those modified to express chimeric antigen receptors (CARs)-to target cancer cells have demonstrated promising responses in clinical trials. However, engineered T cell responses must be regulated to prevent severe side effects such as cytokine storms and off-target responses. Here we present a class of recombinase-based gene circuits that will enable inducible, one-time state switching in adoptive T cell therapy using an FDA-approved drug, creating a generalizable platform that can be used to control when and how strongly a gene is expressed. These circuits exhibit memory such that induced T cells will maintain any changes made even when the drug inducer is removed. This memory feature avoids prolonged drug inducer exposure, thus reducing the complexity and potential side effect associated with the drug inducer. We have utilized these circuits to control the expression of an anti-Her2-CAR, demonstrating the ability of these circuits to regulate CAR expression and T cell activity. We envision this platform can be extended to regulate other genes involved in T cell behavior for applications in various adoptive T cell therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.